GlassScriptPhysician profile
Jennifer A Patton
NPI 1588218739
$2,512.79
in general payments reported to CMS, 2019-2025
20 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $551 · 2022: $124 · 2023: $626 · 2024: $137 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,837.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $408.44 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $263.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $251.89 | 2021-2025 | Farxiga, Airsupra |
| Abbvie INC. | $222.10 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $201.70 | 2025 | |
| Lilly USA, LLC | $197.35 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $154.67 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $137.44 | 2021-2025 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $124.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $124.00 | 2023 | Nuzyra |
| Pfizer INC. | $106.49 | 2024-2025 | |
| Exact Sciences Corporation | $75.61 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Averitas Pharma INC. | $46.00 | 2023 | Qutenza |
| Dynavax Technologies Corporation | $41.58 | 2025 | Heplisav-B |
| Regeneron Healthcare Solutions, INC. | $34.36 | 2025 | Evkeeza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $30.25 | 2025 | Contrave |
| Coloplast Corp | $30.14 | 2025 | |
| Novo Nordisk INC | $28.34 | 2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $19.35 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $15.22 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.